In Vivo Evaluation of 1-O-(4-(2-Fluoroethyl-Carbamoyloxymethyl)-2-Nitrophenyl)-O-β-D-Glucopyronuronate: A Positron Emission Tomographic Tracer for Imaging β-Glucuronidase Activity in a Tumor/Inflammation Rodent Model

Table S1.

[¹⁸F]FEAnGA Kinetics in C6 Gliomas (mean ± SD)

Model		C6 Gliomas > 1.5 cm3 (n = 6)	C6 Gliomas < 1.5 cm3 (n = 8)
Logan	DVT (mL/g)	0.64 ± 0.13*	0.39 ± 0.08
1TCM	K 1	0.06 ± 0.02	0.04 ± 0.02
	DVT (mL/g)	0.58 ± 0.12**	0.33 ± 0.07
	AIC	242 ± 23	228 ± 8
2TCM_reversible	K1/k2 (mL/g)	0.30 ± 0.12	0.24 ± 0.06
	DVT (mL/g)	0.63 ± 0.13**	0.36 ± 0.07
	BPND (k3/k4)	1.4 ± 1.1*	0.6 ± 0.2
	AIC	214 ± 7†	214 ± 13

AIC = Aikake information criterion; BP_ND = binding potential; DV_T = distribution volume; [¹⁸F]FEAnGA = 1-O-(4-(2-fluoroethyl-carbamoyloxymethyl)-2-nitrophenyl)-O-β-D-glucopyronuronate; 1TCM = one-tissue compartment model; 2TCM = two-tissue compartment model.

*

p < .05 compared to gliomas < 1.5 cm³.

**

p < .001 compared to gliomas < 1.5 cm³.

†

p < .001 compared to AIC of 1TCM.